No Data
No Data
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $13
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
Optimistic Buy Rating for OptimizeRx Amid Leadership Transition and Strong Financial Outlook
OptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range
No Data
MARKET-TEST-DUMMY OP :